Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fulvestrant

FDA-approved product (solution, intramuscular), marketed as Cligavyx, Faslodex, Fulvestrant.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Fulvestrant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • HER2 Positive Breast Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-estrogens
FDA pharmacologic class
Estrogen Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fulvestrant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fulvestrant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • (VELA) Study of BLU-222 in Advanced Solid Tumors

    NCT05252416 · start 2022-04-07

    Registered record
    Registry ID
    NCT05252416
    Conditions
    Advanced Solid Tumors; HR+ Breast Cancer; CCNE1 Amplification; HER2-negative Breast Cancer; Ovarian Cancer; Endometrial Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Carcinosarcoma
    Interventions
    BLU-222; Carboplatin; Ribociclib; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-04-07
    Completion
    2025-07-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors; HR+ Breast Cancer; CCNE1 Amplification; HER2-negative Breast Cancer +5 more
    InterventionBLU-222; Carboplatin; Ribociclib; Fulvestrant
    PhasePhase 1
    Registry statusTerminated

  • Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients

    NCT05680194 · start 2022-04-01

    Registered record
    Registry ID
    NCT05680194
    Conditions
    Breast Cancer Female
    Interventions
    operation; Bisphosphonate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-04-01
    Completion
    2025-12-01
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Female
    Interventionoperation; Bisphosphonate
    PhaseNot recorded
    Registry statusUnknown

  • A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy

    NCT05853432 · start 2022-03-16

    Registered record
    Registry ID
    NCT05853432
    Conditions
    HR+/HER2- Advanced or Metastatic Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-03-16
    Completion
    2022-05-02
    Enrolment
    157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHR+/HER2- Advanced or Metastatic Breast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

    NCT05343117 · start 2021-12-01

    Registered record
    Registry ID
    NCT05343117
    Conditions
    Hormone Receptor Positive Advanced Breast Cancer
    Interventions
    Palbociclib based-therapy as initial endocrine therapy; Palbociclib based-therapy after chemotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-12-01
    Completion
    2024-06-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone Receptor Positive Advanced Breast Cancer
    InterventionPalbociclib based-therapy as initial endocrine therapy; Palbociclib based-therapy after chemotherapy
    PhaseNot recorded
    Registry statusUnknown

  • Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

    NCT04738292 · start 2021-10-05

    Registered record
    Registry ID
    NCT04738292
    Conditions
    ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Cancer
    Interventions
    Onapristone; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-10-05
    Completion
    2023-05-15
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Cancer
    InterventionOnapristone; Fulvestrant
    PhasePhase 2
    Registry statusTerminated

  • Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

    NCT05063786 · start 2021-09-14

    Registered record
    Registry ID
    NCT05063786
    Conditions
    Advanced Breast Cancer
    Interventions
    Trastuzumab; Alpelisib; Fulvestrant; Vinorelbine; Capecitabine; Eribulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-09-14
    Completion
    2026-06
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionTrastuzumab; Alpelisib; Fulvestrant; Vinorelbine +2 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

    NCT04916509 · start 2021-09-13

    Registered record
    Registry ID
    NCT04916509
    Conditions
    Breast Neoplasms
    Interventions
    Palbociclib plus an aromatase inhibitor; Palbociclib plus fulvestrant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-09-13
    Completion
    2022-12-27
    Enrolment
    258

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionPalbociclib plus an aromatase inhibitor; Palbociclib plus fulvestrant
    PhaseNot recorded
    Registry statusCompleted

  • The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

    NCT04753177 · start 2021-01-28

    Registered record
    Registry ID
    NCT04753177
    Conditions
    The Neoadjuvant Therapy
    Interventions
    Ribocyclib, fulvestrant, triptorelin; Doxorubicin, cyclophosphamide, paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2021-01-28
    Completion
    2024-01-28
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThe Neoadjuvant Therapy
    InterventionRibocyclib, fulvestrant, triptorelin; Doxorubicin, cyclophosphamide, paclitaxel
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

    NCT04282031 · start 2020-06-15

    Registered record
    Registry ID
    NCT04282031
    Conditions
    Advanced Solid Tumor; HR+/HER2- Breast Cancer
    Interventions
    BPI-1178; Fulvestrant; Letrozole; BPI-1178
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2020-06-15
    Completion
    2025-06-30
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor; HR+/HER2- Breast Cancer
    InterventionBPI-1178; Fulvestrant; Letrozole; BPI-1178
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

    NCT04247126 · start 2020-01-23

    Registered record
    Registry ID
    NCT04247126
    Conditions
    Advanced Solid Tumor; Breast Cancer; Small-cell Lung Cancer; Pancreatic Cancer
    Interventions
    SY-5609; Fulvestrant; Gemcitabine; Nab-paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-23
    Completion
    2023-03-30
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor; Breast Cancer; Small-cell Lung Cancer; Pancreatic Cancer
    InterventionSY-5609; Fulvestrant; Gemcitabine; Nab-paclitaxel
    PhasePhase 1
    Registry statusCompleted

  • Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

    NCT04526028 · start 2019-09-13

    Registered record
    Registry ID
    NCT04526028
    Conditions
    Breast Cancer; Fulvestrant; Palbociclib
    Interventions
    Fulvestrant Injectable Product; Palbociclib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-09-13
    Completion
    2023-05-31
    Enrolment
    612

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Fulvestrant; Palbociclib
    InterventionFulvestrant Injectable Product; Palbociclib
    PhaseNot recorded
    Registry statusUnknown

  • FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study

    NCT03926936 · start 2019-03-13

    Registered record
    Registry ID
    NCT03926936
    Conditions
    Endometrial Stromal Sarcoma; Adenosarcoma of Uterus; Leiomyosarcoma Uterus; Endometrial Cancer; Sex Cord Stromal Tumor; Serous Ovarian Tumor
    Interventions
    Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-03-13
    Completion
    2022-12-27
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Stromal Sarcoma; Adenosarcoma of Uterus; Leiomyosarcoma Uterus; Endometrial Cancer +2 more
    InterventionFulvestrant
    PhasePhase 2
    Registry statusCompleted

  • A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

    NCT03584009 · start 2018-09-06

    Registered record
    Registry ID
    NCT03584009
    Conditions
    Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
    Interventions
    Venetoclax; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-09-06
    Completion
    2021-05-06
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
    InterventionVenetoclax; Fulvestrant
    PhasePhase 2
    Registry statusTerminated

  • Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

    NCT03750396 · start 2018-08-01

    Registered record
    Registry ID
    NCT03750396
    Conditions
    Breast Cancer; Recurrent Breast Cancer; Stereotactic Body Radiotherapy; Estrogen Receptor Positive Tumor; Her2-negative Tumor; Surgery
    Interventions
    Surgical resection; Stereotactic body radiotherapy; Radiofrequency ablation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-08-01
    Completion
    2025-07-31
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Recurrent Breast Cancer; Stereotactic Body Radiotherapy; Estrogen Receptor Positive Tumor +2 more
    InterventionSurgical resection; Stereotactic body radiotherapy; Radiofrequency ablation
    PhasePhase 2
    Registry statusUnknown

  • Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

    NCT03308201 · start 2017-10-16

    Registered record
    Registry ID
    NCT03308201
    Conditions
    Breast Cancer
    Interventions
    Hemay022+exemestane; Hemay022+letrozole; Hemay022+ fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-16
    Completion
    2023-03-01
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionHemay022+exemestane; Hemay022+letrozole; Hemay022+ fulvestrant
    PhasePhase 1
    Registry statusCompleted